Thrombolytic treatment with tissue plasminogen activators (tPA) has been approved by the U.S. Food and Drug Administration as a standard treatment for cerebral infarction, and its therapeutic time window has recently been expanded to 4.5 h after onset [1]. The gene discussed is PLAT; the disease is cerebral infarction.